References
- Orazi A, Hasserjian RP, Cazzola M, Thiele M, Malcovati L.,
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and
thrombocytosis. WHO Classification of Tumours of Haematopoietic and
Lymphoid Tissues. Revised 4th ed, Lyon, International Agency for
Research on Cancer. 2017; 93-94.
- Swerdlow SH, Campo E, Harris NL, et al, ed. WHO classification of
tumours of haematopoietic and lymphoid tissues, Lyon, France:
International Agency for Research on Cancer, 2017.
- Broseus J, Florensa L, Zipperer E, et al. Clinical features and course
of refractory anemia with ring sideroblasts associated with marked
thrombocytosis. Haematologica 2012; 97:1036-1041.
- Jeromin S, Haferlach T, Weissmann S. “Refractory anemia with ring
sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1
or other spliceosome genes accompanied by JAK2V617F and ASXL1mutations”, Haematologica. 2015; 100: pp. e125-e127.
- Patnaik MM, Tefferi A, Myelodysplastic syndromes with ring
sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and
thrombocytosis (MDS/MPN-RS-T) – 2021 update on diagnosis,
risk-stratification, and management. Am J Hematol . 2021; 96:
379–394.
- Visconte, V., Avishai, N., Mahfouz, R. et al. Distinct iron
architecture in SF3B1-mutant myelodysplastic syndrome patients is
linked to an SLC25A37 splice variant with a retained
intron. Leukemia . 2015; 29: 188–195.
- Oh ST, Gotlib J, JAK2 V617F and beyond: role of genetics and aberrant
signaling in the pathogenesis of myeloproliferative
neoplasms. Expert Review of Hematology . 2010; 3: 323-337.
- Pati, H, Veetil KK. Myelodysplastic Syndrome/Myeloproliferative
Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic
Mechanisms and Their Implications. Indian J Hematol Blood
Transfus. 2019; 35: 3–11.
- Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of
calreticulin in 206 myeloproliferative neoplasms. N Engl J Med.2013; 369:2379–2390.
- J. Broséus, E. Lippert, A.S. Harutyunyan, et al. “Low rate of
calreticulin mutations in refractory anaemia with ring sideroblasts
and marked thrombocytosis”. Leukemia , 2014; 6: 1374–1376.
- Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in
myeloproliferative and other 209 myeloid disorders: a study of 1182
patients. Blood . 2006;108: 3472–3476.
- S. Schnittger, U. Bacher, C. Haferlach, et al. “Detection of an
MPLW515 mutation in a case with features of both essential
thrombocythemia and refractory anemia with ringed sideroblasts and
thrombocytosis”, Leukemia , vol. 22, no. 2, pp. 453–455, 2008.
- Ernst T, Chase AJ, Score J, et al. Inactivating 212 mutations of the
histone methyltransferase gene EZH2 in myeloid disorders. Nat
Genet . 2010; 42: 22–213.
- Abdel-Wahab O, Adli M, LaFave et al., ASXL1 mutations 216 promote
myeloid transformation through loss of PRC2-mediated gene repression.Cancer Cell. 2012; 22:180–193.
- Figueroa ME, Abdel-Wahab O, Lu C, et al., Leukemic IDH1 and 220 IDH2
mutations result in a hypermethylation phenotype, disrupt TET2
function, and impair hematopoietic 221 differentiation. Cancer
Cell . 2010; 18: 553–567.
- Broseus J, Florensa L, Zipperer E, et. al. Clinical features 183 and
course of refractory anemia with ring sideroblasts associated with
marked thrombocytosis. Haematologica . 2012; 97: 1036–41.
- van Genderen PJJ, Michiels JJ. Erythromelalgia: A pathognomonic
microvascular thrombotic complication in essential thrombocythemia and
polycythemia vera. Semin Thromb Hemost. 1997; 23: 357-363.
- Patnaik MM, Lasho TL, CM , et al., Vascular events and risk factors
for thrombosis in refractory anemia with ring sideroblasts and
thrombocytosis. Leukemia . 2016; 30: 2273-2275.
- Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment
algorithm. 2018. Blood Cancer J. 2018; 10: 2.
- Alvarez-Larran A, Cervantes F, Pereira A, et al., Observation versus
antiplatelet therapy as primary prophylaxis for thrombosis in low-risk
essential thrombocythemia. Blood . 2010; 116:1205-1210.
- Pascale S, Petrucci G, Dragani A, et al., Aspirin-insensitive
thromboxane biosynthesis in essential thrombocythemia is explained by
accelerated renewal of the drug target. Blood . 2012: 119:
3595-3603.
- Awada H, Voso MT, Guglielmelli P, Gurnari C. Essential Thrombocythemia
and Acquired von Willebrand Syndrome: The Shadowlands between
Thrombosis and Bleeding. Cancers . 2020; 12:1746.
- Nicolosi M, Mudireddy M, Vallapureddy R, et. al., Lenalidomide therapy
in patients with myelodysplastic syndrome/myeloproliferative neoplasm
with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)”, Am J
Hematol . 2018; 93: pp. E27-E30.
- G. Huls, A.B. Mulder, S. Rosati, A.A. van de Loosdrecht, E. Vellenga,
J.T. de Wolf. “Efficacy of single-agent lenalidomide in patients with
JAK2 (V617F) mutated refractory anemia with ring sideroblasts and
thrombocytosis”. Blood . Vol.116, no.2, pp. 180-182, 2010.
- M.M. Patnaik, A. Tefferi, “Refractory anemia with ring sideroblasts
(RARS) and RARS with thrombocytosis (RARS-T): 2017 update on
diagnosis, risk-stratification, and management”, Am J Hematol .
2017;Vol. 92: 297–310.
- Moyo V, Lefebvre P, Duh MS, et. al. Erythropoiesis- stimulating agents
in the treatment of anemia in myelodysplastic syndromes: a
meta-analysis. Ann Hematol . 2008; 87:527-536.
- Komorkji RS, Luspatercept in Myelodysplastic Syndromes: Who and
When?Hematol Oncol Clin North Am. 2020; 34: 393-400.
- Sharma P, Shinde SS, Damlaj M, et al., Allogeneic hematopoietic stem
cell transplant in adult patients with myelodysplastic syndrome/
myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leuk
Lymphoma . 2016; 58: 872-881.